Review



cxcl10 treatment group  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress cxcl10 treatment group
    Cxcl10 Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cxcl10+treatment+group/IP-10%2FCXCL10%2C+Human/10__1080_slash_2162402x__2025__2539442-63-3-13
    Average 93 stars, based on 3 article reviews
    cxcl10 treatment group - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Control:

    Article Title: Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 <sup>+</sup> T cell infiltration
    Article Snippet: .. Control group (PBS); CXCL10 treatment group (50 μg/kg, intratumoral injection, every 3 days, MCE, HY-P7226); FAK inhibitor treatment group (100 mg/kg, oral gavage, once daily, Sellect, S7654); Combination therapy group (anti-PD-1 (200 μg, intraperitoneal injection, every 3 days, Bioxcell, CP157) and VS-6063 (100 mg/kg, oral gavage, once daily, Sellect, S7654). ..

    Article Title: Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 + T cell infiltration
    Article Snippet: .. Control group (PBS); CXCL10 treatment group (50 μg/kg, intratumoral injection, every 3 days, MCE, HY-P7226); FAK inhibitor treatment group (100 mg/kg, oral gavage, once daily, Sellect, S7654); Combination therapy group (anti-PD-1 (200 μg, intraperitoneal injection, every 3 days, Bioxcell, CP157) and VS-6063 (100 mg/kg, oral gavage, once daily, Sellect, S7654). ..

    Injection:

    Article Title: Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 <sup>+</sup> T cell infiltration
    Article Snippet: .. Control group (PBS); CXCL10 treatment group (50 μg/kg, intratumoral injection, every 3 days, MCE, HY-P7226); FAK inhibitor treatment group (100 mg/kg, oral gavage, once daily, Sellect, S7654); Combination therapy group (anti-PD-1 (200 μg, intraperitoneal injection, every 3 days, Bioxcell, CP157) and VS-6063 (100 mg/kg, oral gavage, once daily, Sellect, S7654). ..

    Article Title: Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 + T cell infiltration
    Article Snippet: .. Control group (PBS); CXCL10 treatment group (50 μg/kg, intratumoral injection, every 3 days, MCE, HY-P7226); FAK inhibitor treatment group (100 mg/kg, oral gavage, once daily, Sellect, S7654); Combination therapy group (anti-PD-1 (200 μg, intraperitoneal injection, every 3 days, Bioxcell, CP157) and VS-6063 (100 mg/kg, oral gavage, once daily, Sellect, S7654). ..



    Similar Products

    cxcl10 treatment group  (MedChemExpress)
    93
    MedChemExpress cxcl10 treatment group
    Cxcl10 Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cxcl10+treatment+group/IP-10%2FCXCL10%2C+Human/10__1080_slash_2162402x__2025__2539442-63-3-13
    Average 93 stars, based on 1 article reviews
    cxcl10 treatment group - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results